Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Breakthrough Troubles Emerge In Effort To Speed Development

Executive Summary

Inspection schedules, diagnostic review and other issues have emerged as some of FDA’s breakthrough therapy designees wend their way closer to the review and approval stages, and FDA says more guidance will be needed.

You may also be interested in...



PDUFA V ‘Program’ Gets Positive Evaluation – Except For Inspections

Longer application review time has been producing the improved communication sponsors expected, but modifications to the user fee program have yet to make inspections go smoother.

Breakthrough Therapies: FDA Not Writing A Scientific Guidance – Yet

The agency needs more experience making the decisions before it lays out the evidence threshold for a breakthrough designation, CDER Director Janet Woodcock says.

For Combination Product Development, Industry Says Talk Is Cheap

Industry official says FDA is responsive to questions from sponsors, but should issue more written guidance to help sponsors make development decisions.

Topics

Related Companies

UsernamePublicRestriction

Register

PS055509

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel